Patents Assigned to Pfizer
  • ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES
    Publication number: 20180296691
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: January 22, 2018
    Publication date: October 18, 2018
    Applicants: PFIZER, INC., ABBVIE STEMCENTRX LLC
    Inventors: Marc Isaac DAMELIN, Kiran Manohar KHANDKE, Puja SAPRA, Alexander John BANKOVICH, Scott J. DYLLA
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20180296585
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 18, 2018
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • THERAPEUTIC ANTIBODIES AND THEIR USES
    Publication number: 20180298108
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 18, 2018
    Applicant: PFIZER INC.
    Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
  • Vectors for expression of prostate-associated antigens
    Patent number: 10092636
    Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 9, 2018
    Assignee: Pfizer Inc.
    Inventor: Joseph John Binder
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 10093655
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 9, 2018
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Michael Eric Green, Jaclyn Louise Henderson, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Lei Zhang
  • Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
    Publication number: 20180282415
    Abstract: The present disclosure describes combination therapies useful for the treatment of cancer. In particular, the invention relates to a combination therapy which comprises a PD-1 axis binding antagonist and an ALK inhibitor for treating cancer.
    Type: Application
    Filed: September 27, 2016
    Publication date: October 4, 2018
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Chia-Yang LIN, Wei Wei Wu PRIOR, Yan QU, Changyu WANG
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180282304
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 4, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Bifunctional cytotoxic agents
    Patent number: 10086085
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 2, 2018
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20180273504
    Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 29, 2016
    Publication date: September 27, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
    Patent number: 10080723
    Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: September 25, 2018
    Assignee: Pfizer Inc.
    Inventors: Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Young-ho Song, Hong Wang
  • CELLS AND METHOD OF CELL CULTURE
    Publication number: 20180265904
    Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 20, 2018
    Applicant: PFIZER INC.
    Inventors: GREGORY WALTER HILLER, JEFFREY JOSEPH MITCHELL, BHANU CHANDRA MULUKUTLA, PAMELA MARY PEGMAN
  • Imidazopyridazine compounds
    Patent number: 10077269
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: September 18, 2018
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young, Patrick Robert Verhoest
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 10077272
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 18, 2018
    Assignee: Pfizer Inc.
    Inventors: David Lawrence Firman Gray, Lei Zhang, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, Chewah Lee, Scot Richard Mente, Steven Victor O'Neil, Bruce Nelsen Rogers, Chakrapani Subramanyam
  • DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS
    Publication number: 20180258081
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Applicant: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same
    Publication number: 20180256584
    Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of pemetrexed; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 13, 2018
    Applicant: Pfizer Inc.
    Inventor: Stephen E. Zale
  • Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
    Patent number: 10071100
    Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: September 11, 2018
    Assignee: Pfizer Inc.
    Inventors: Shubha Bagrodia, Jennifer Lafontaine, Zach Lovatt, Eyoung Shin, Young Ho Song, Greg Troiano, Hong Wang
  • Cancer cell targeting using nanoparticles
    Patent number: 10071056
    Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: September 11, 2018
    Assignee: Pfizer Inc.
    Inventors: Stephen E. Zale, Mir Mukkaram Ali
  • Diacylglycerol acyl transferase 2 inhibitors
    Patent number: 10071992
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 11, 2018
    Assignee: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • Bottle with flip top closure
    Patent number: D830835
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 16, 2018
    Assignee: Pfizer Inc.
    Inventor: Matthew Clifton Keller
  • Bottle with flip top closure
    Patent number: D830836
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 16, 2018
    Assignee: Pfizer Inc.
    Inventor: Matthew Clifton Keller